Goldline Pharmaceutical launched its initial public offering (IPO) on May 12, 2026, aiming to raise ₹11.61 crore. The shares are priced in the band of ₹41 to ₹43 each. According to grey market trends, the stock could debut at around ₹60, indicating investor interest. The funds raised through the IPO will primarily be used to reduce the company's existing debt and to cover corporate expenses. Investors who apply can expect the allotment results to be declared by May 15, 2026. This IPO is part of the SME segment, providing an opportunity for investors to participate in the pharmaceutical sector's growth.